Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Halo-Lido (CITI-002) in Grade II or III Hemorrhoids
NCT05348200Phase 2Completed
- Sponsor
- Citius Pharmaceuticals, Inc.
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Halobetasol propionate 0.05% lotion, lidocaine 10% oropharyngeal spray in Hemorrhoids, sponsored by Citius Pharmaceuticals, Inc.. Started Apr 2022; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotionlidocaine 10% oropharyngeal spray
03
Conditions
Hemorrhoids
Beyond the preview
Go deeper on NCT05348200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348200.